Executive Interviews

  1. What’s Necessary To Realize The Promise Of Digital Health Solutions?
    8/30/2019

    Representatives from the National Kidney Foundation, Bayer, and digital health startup up, Bitome, share their views on what’s necessary to realize the promise of innovative digital health solutions toward treating the whole patient during an educational panel session at the 2019 BIO International Convention And Conference.

  2. Jeremy Levin Weighs In On Biosimilar Patent Thicket
    8/30/2019

    At the 2019 BIO Conference Chief Editor Rob Wright sat down with newly elected board-director chair, Jeremy Levin, DPhil, MB, BChir, CEO of Ovid Therapeutics to talk patent thickets and his role with BIO.

  3. The Story Of Pfizer’s R&D Turnaround
    8/30/2019

    Mikael Dolsten, M.D., Ph.D., CSO and president, worldwide research, development and medical (WRDM), reveals the decade long turnaround of the Pfizer’s R&D innovation engine leading to what could be the company’s best ever pipeline.

  4. Athira’s Whole-Patient Drug Development
    8/30/2019

    One company is atypical in the industry for its use of patient and caregiver input to guide its drug-development journey. That shows in the program for its lead drug entering later-stage trials in treating Alzheimer’s disease.

  5. CDMO-To-Hospital: A Direct Ending For Generic Shortages?
    8/1/2019

    Part 2 of our look at the unique business model and ambitious plans of Civica Rx.

  6. Strategies For Success: Developing Drugs For Orphan Diseases
    8/1/2019

    Drug development, in general, is a challenging feat. When it comes to orphan drugs, however, those challenges are compounded. As more orphan drugs are developed, pharma companies can tap into some of the successful strategies that have worked previously.

  7. How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell Therapy
    8/1/2019

    Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful serial entrepreneur, including his most recent biopharma venture — Celularity Therapeutics.

  8. A Second Career As A Biotech CEO
    8/1/2019

    “This was a real turnaround type of challenge, and I knew it was going to be a steep learning curve for me,” says Steven Yatomi-Clarke of Prescient Therapeutics. “In fact, at the time, I probably underestimated the amount of work it was going to take to get the company up to scratch.”

  9. Increasing Diversity Among Leadership And Boards
    7/1/2019

    Biopharmaceutical executives Ron Cohen, Acorda Therapeutics; John Maraganore, Alnylam; and Helen Torley, Halozyme Therapeutics, discuss BIO’s approach toward increasing diversity among the industry’s leadership.

  10. Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit
    7/1/2019

    The nonprofit CivicaRX continues to gain momentum, and the company’s president and CEO, Martin Van Trieste, believes it’s a business model that is “pro-competition,” and one that others throughout the biopharma industry can adapt as well.